D-dimer elevation and paresis predict thromboembolic events during bevacizumab therapy for recurrent malignant glioma

Anticancer Research

Volumn 33, Issue 5, 2013, Pages 2093-2098

  Misch, Martin ^a   Czabanka, Marcus ^a   Dengler, Julius ^a   Stoffels, Mandy ^a   Auf, Gregor ^a   Vajkoczy, Peter ^a   Stockhammer, Florian ^a,b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

Author keywords

Bevacizumab; D dimer; Deep venous thrombosis; Recurrent malignant glioma

Indexed keywords

BEVACIZUMAB; D DIMER; ENZASTAURIN; IRINOTECAN; NADROPARIN; NITROSOUREA; SUNITINIB; TEMOZOLOMIDE;

ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CLINICAL ARTICLE; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DIARRHEA; DRUG DOSE REDUCTION; DRUG INDUCED DISEASE; DRUG WITHDRAWAL; FATIGUE; FEMALE; GLIOBLASTOMA; HEMIPARESIS; HUMAN; LOW DRUG DOSE; LUNG EMBOLISM; MALE; NAUSEA; PRIORITY JOURNAL; RECURRENT CANCER; RETROSPECTIVE STUDY; SALVAGE THERAPY; SIDE EFFECT;

BEVACIZUMAB; D-DIMER; DEEP VENOUS THROMBOSIS; RECURRENT MALIGNANT GLIOMA;

ADULT; AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; BRAIN NEOPLASMS; FEMALE; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; FOLLOW-UP STUDIES; GLIOMA; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PARESIS; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS; THROMBOEMBOLISM;

EID: 84878166747     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, Ludwin SK, Allgeier A, Fisher B, Belanger K, Hau P, Brandes AA, Gijtenbeek J, Marosi C, Vecht CJ, Mokhtari K, Wesseling P, Villa S, Eisenhauer E, Gorlia T, Weller M, Lacombe D, Cairncross JG and Mirimanoff RO: Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-Year analysis of the EORTC-NCIC trial. Lancet Oncol 10: 459-466, 2009.
2. Stummer W, Nestler U, Stockhammer F, Krex D, Kern BC, Mehdorn HM, Vince GH and Pichlmeier U: Favorable outcome in the elderly cohort treated by concomitant temozolomide radiochemotherapy in a multicentric phase II safety study of 5- ALA. J Neurooncol 103: 361-370, 2011.
3. Kreisl TN, Kim L, Moore K, Duic P, Royce C, Stroud I, Garren N, Mackey M, Butman JA, Camphausen K, Park J, Albert PS and Fine HA: Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol 27: 740-745, 2009.
4. Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE, Yung WK, Paleologos N, Nicholas MK, Jensen R, Vredenburgh J, Huang J, Zheng M and Cloughesy T: Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma. J Clin Oncol 27: 4733-4740, 2009.
5. Vredenburgh JJ, Desjardins A, Herndon JE, 2nd, Dowell JM, Reardon DA, Quinn JA, Rich JN, Sathornsumetee S, Gururangan S, Wagner M, Bigner DD, Friedman AH and Friedman HS: Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res 13: 1253-1259, 2007. (Pubitemid 46424067)
6. Johansson F, Ekman S, Blomquist E, Henriksson R, Bergstrom S and Bergqvist M: A review of dose-dense temozolomide alone and in combination with bevacizumab in patients with first relapse of glioblastoma. Anticancer Res 32: 4001-4006, 2012.
7. Balana C, Etxaniz O, Buges C and Martinez A: Approval denied by the European Medicines Agency (EMA) for bevacizumab in the treatment of high-grade glioma recurrence: A good idea or a grave error? Clin Transl Oncol 13: 209-210, 2011.
8. Stockhammer F, Misch M, Koch A, Czabanka M, Plotkin M, Blechschmidt C, Tuettenberg J and Vajkoczy P: Continuous lowdose temozolomide and celecoxib in recurrent glioblastoma. J Neurooncol 100: 407-415, 2010.
9. Wick W, Platten M and Weller M: New (alternative) temozolomide regimens for the treatment of glioma. Neurooncol 11: 69-79, 2009.
10. Perry JR, Rizek P, Cashman R, Morrison M and Morrison T: Temozolomide rechallenge in recurrent malignant glioma by using a continuous temozolomide schedule: The rescue approach. Cancer 113: 2152-2157, 2008.
11. Glas M, Hundsberger T, Stuplich M, Wiewrodt D, Kurzwelly D, Nguyen-Huu B, Rasch K and Herrlinger U: Nimustine (ACNU) plus teniposide (VM26) in recurrent glioblastoma. Oncology 76: 184-189, 2009.
12. Schmidt F, Fischer J, Herrlinger U, Dietz K, Dichgans J and Weller M: PCV chemotherapy for recurrent glioblastoma. Neurology 66: 587-589, 2006. (Pubitemid 43739895)
13. Chinot OL, de La Motte Rouge T, Moore N, Zeaiter A, Das A, Phillips H, Modrusan Z and Cloughesy T: AVAglio: Phase 3 trial of bevacizumab plus temozolomide and radiotherapy in newly diagnosed glioblastoma multiforme. Adv Ther 28: 334-340, 2011.
14. Chinot O, Wick W, Mason W, Henriksson R, Saran F, Nishikawa R, Hilton M, Abrey L and Cloughesy T: Phase III Trial of Bevacizumab added to Standard Radiotherapy and Temozolomide for Newly-Diagnozed Glioblastoma: Mature Progression-Free Survival and Prelimitary Overall Survival Results in AVAglio. Neurooncol 14: 101-101, 2012.
15. Scappaticci FA, Skillings JR, Holden SN, Gerber HP, Miller K, Kabbinavar F, Bergsland E, Ngai J, Holmgren E, Wang J and Hurwitz H: Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst 99: 1232-1239, 2007. (Pubitemid 47299901)
16. Zangari M, Fink LM, Elice F, Zhan F, Adcock DM and Tricot GJ: Thrombotic events in patients with cancer receiving antiangiogenesis agents. J Clin Oncol 27: 4865-4873, 2009.
17. Khorana AA, Kuderer NM, Culakova E, Lyman GH and Francis CW: Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood 111: 4902-4907, 2008.
18. Ay C, Vormittag R, Dunkler D, Simanek R, Chiriac AL, Drach J, Quehenberger P, Wagner O, Zielinski C and Pabinger I: D-Dimer and prothrombin fragment 1+2 predict venous thromboembolism in patients with cancer: Results from the Vienna Cancer and Thrombosis Study. J Clin Oncol 27: 4124-4129, 2009.
19. Arpaia G, Carpenedo M, Verga M, Mastrogiacomo O, Fagnani D, Lanfredini M, Milani M and Cimminiello C: D-Dimer before chemotherapy might predict venous thromboembolism. Blood Coagul Fibrinolysis 20: 170-175, 2009.
20. Le Gal G, Righini M, Roy PM, Sanchez O, Aujesky D, Bounameaux H and Perrier A: Prediction of pulmonary embolism in the emergency department: The revised Geneva score. Ann Intern Med 144: 165-171, 2006. (Pubitemid 46780688)
21. Medical Research Council: Aids to the examination of the peripheral nervous system. Her Majesty's Stationary Office, London, 1981.
22. Norden AD, Young GS, Setayesh K, Muzikansky A, Klufas R, Ross GL, Ciampa AS, Ebbeling LG, Levy B, Drappatz J, Kesari S and Wen PY: Bevacizumab for recurrent malignant gliomas: Efficacy, toxicity, and patterns of recurrence. Neurology 70: 779-787, 2008.
23. Vredenburgh JJ, Desjardins A, Herndon JE, 2nd, Marcello J, Reardon DA, Quinn JA, Rich JN, Sathornsumetee S, Gururangan S, Sampson J, Wagner M, Bailey L, Bigner DD, Friedman AH and Friedman HS: Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 25: 4722-4729, 2007. (Pubitemid 350086473)
24. Semrad TJ, O'Donnell R, Wun T, Chew H, Harvey D, Zhou H and White RH: Epidemiology of venous thromboembolism in 9489 patients with malignant glioma. J Neurosurg 106: 601-608, 2007. (Pubitemid 46536455)
25. Simanek R, Vormittag R, Hassler M, Roessler K, Schwarz M, Zielinski C, Pabinger I and Marosi C: Venous thromboembolism and survival in patients with high-grade glioma. Neurooncol 9: 89-95, 2007. (Pubitemid 46580310)
26. Lai A, Filka E, McGibbon B, Nghiemphu PL, Graham C, Yong WH, Mischel P, Liau LM, Bergsneider M, Pope W, Selch M and Cloughesy T: Phase II pilot study of bevacizumab in combination with temozolomide and regional radiation therapy for up-front treatment of patients with newly diagnosed glioblastoma multiforme: Interim analysis of safety and tolerability. Int J Radiat Oncol Biol Phys 71: 1372-1380, 2008.
27. Kuenen BC: Analysis of prothrombotic mechanisms and endothelial perturbation during treatment with angiogenesis inhibitors. Pathophysiol Haemost Thromb 33: 13-14, 2003.
28. Yang R, Thomas GR, Bunting S, Ko A, Ferrara N, Keyt B, Ross J and Jin H: Effects of vascular endothelial growth factor on hemodynamics and cardiac performance. J Cardiovasc Pharmacol 27: 838-844, 1996. (Pubitemid 26000416)
29. Meyer T, Robles-Carrillo L, Robson T, Langer F, Desai H, Davila M, Amaya M, Francis JL and Amirkhosravi A: Bevacizumab immune complexes activate platelets and induce thrombosis in FCGR2A transgenic mice. J Thromb Haemost 7: 171-181, 2009.
30. Keefe D, Bowen J, Gibson R, Tan T, Okera M and Stringer A: Noncardiac vascular toxicities of vascular endothelial growth factor inhibitors in advanced cancer: A review. Oncologist 16: 432-444, 2011.
31. Nghiemphu PL, Green RM, Pope WB, Lai A and Cloughesy TF: Safety of anticoagulation use and bevacizumab in patients with glioma. Neurooncol 10: 355-360, 2008.
32. Gerber DE, Grossman SA and Streiff MB: Management of venous thromboembolism in patients with primary and metastatic brain tumors. J Clin Oncol 24: 1310-1318, 2006. (Pubitemid 46622035)
33. Perry JR, Julian JA, Laperriere NJ, Geerts W, Agnelli G, Rogers LR, Malkin MG, Sawaya R, Baker R, Falanga A, Parpia S, Finch T and Levine MN: PRODIGE: A randomized placebo-controlled trial of dalteparin low-molecular-weight heparin thromboprophylaxis in patients with newly diagnosed malignant glioma. J Thromb Haemost 8: 1959-1965, 2010.
34. Rank A, Liebhardt S, Zwirner J, Burges A, Nieuwland R and Toth B: Circulating microparticles in patients with benign and malignant ovarian tumors. Anticancer Res 32: 2009-2014, 2012.